Quick Answer
Arcturus Therapeutics Holdings Inc. reported Research And Development Expense of $112.21 million for the year ending 2025.
- Arcturus Therapeutics Holdings Inc. showed a decrease of -42.5% in Research And Development Expense from 2024 to 2025.
- This data is from Arcturus Therapeutics Holdings Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $4.23 million | Q3 2018: $3.97 million | Q1 2019: $7.32 million | Q2 2019: $7.27 million | Q3 2019: $7.05 million | Q4 2019: $11.99 million | Q1 2020: $7.92 million | Q2 2020: $7.94 million | Q3 2020: $17.70 million | Q4 2020: $24.29 million | Q1 2021: $50.05 million | Q2 2021: $45.68 million | Q3 2021: $45.40 million | Q4 2021: $32.63 million | Q1 2022: $44.89 million | Q2 2022: $38.19 million | Q3 2022: $37.69 million | Q1 2023: $51.77 million | Q2 2023: $52.67 million | Q3 2023: $51.08 million | Q1 2024: $53.57 million | Q2 2024: $58.67 million | Q3 2024: $39.13 million | Q1 2025: $34.89 million | Q2 2025: $29.58 million | Q3 2025: $23.27 million.
- Over the full 8 years of available data (2018 to 2025), Arcturus Therapeutics Holdings Inc.'s Research And Development Expense has grown by 560.8%.
- Historical annual values: Fiscal year 2025: $112.21 million | Fiscal year 2024: $195.16 million | Fiscal year 2023: $192.13 million | Fiscal year 2022: $147.75 million | Fiscal year 2021: $173.76 million | Fiscal year 2020: $57.85 million | Fiscal year 2019: $33.64 million | Fiscal year 2018: $16.98 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: